DSIJ Mindshare

Alembic Pharma gets US regulator nod for Doxepin Hydrochloride capsules

Anthony Fernandes 0 813 Article rating: 5.0

On Friday, Alembic Pharmaceuticals informed the exchanges that it has received final approval from US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA), Doxepin Hydrochloride capsules, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg & 100 mg.  

RSS
First30723073307430753077307930803081Last
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR